After 10 months, Alnylam still can't explain patient trial deaths

More than 10 months after disclosing that patients who received one of its experimental drugs in a late-stage trial had died at a far higher rate than those on placebo, Cambridge-based Alnylam Pharmaceuticals still cannot conclusively explain what went wrong. Alnylam (Nasdaq: ALNY) on Wednesday released the results of its investigation into the deaths of older patients with heart problems who took revusiran, a potential treatment for a deadly inherited disease called hATTR cardiomyopathy. In October,…
Source: bizjournals.com Health Care:Physician Practices headlines - Category: American Health Authors: Source Type: news